IDH1 Non-Canonical Mutations and Survival in Patients with Glioma

Background: Non-canonical mutations of the isocitrate dehydrogenase (IDH) genes have been described in about 20–25% and 5–12% of patients with WHO grade II and III gliomas, respectively. To date, the prognostic value of these rare mutations is still a topic of debate. Methods: We selected patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Franceschi, Enrico, De Biase, Dario, Di Nunno, Vincenzo, Pession, Annalisa, Tosoni, Alicia, Gatto, Lidia, Tallini, Giovanni, Visani, Michela, Lodi, Raffaele, Bartolini, Stefania, Brandes, Alba Ariela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922632/
https://www.ncbi.nlm.nih.gov/pubmed/33669525
http://dx.doi.org/10.3390/diagnostics11020342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922632/
https://www.ncbi.nlm.nih.gov/pubmed/33669525
http://dx.doi.org/10.3390/diagnostics11020342

Ejemplares similares